The latest price target for Rigel Pharmaceuticals (NASDAQ:RIGL) was reported by Jefferies on November 5, 2025. The analyst firm set a price target for $42.00 expecting RIGL to rise to within 12 months (a possible 2.51% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Rigel Pharmaceuticals (NASDAQ:RIGL) was provided by Jefferies, and Rigel Pharmaceuticals upgraded their buy rating.

The last upgrade for Rigel Pharmaceuticals Inc happened on November 5, 2025 when Jefferies raised their price target to $42. Jefferies previously had a hold for Rigel Pharmaceuticals Inc.

There is no last downgrade for Rigel Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on November 5, 2025 so you should expect the next rating to be made available sometime around November 5, 2026.

While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a upgraded with a price target of $23.00 to $42.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $40.97, which is within the analyst’s predicted range.